FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal flui...

Full description

Saved in:
Bibliographic Details
Main Authors VENKATA SATYANARAYANA APPADWEDULA, VENKAIAH CHOWDARY NANNAPANENI, KALI SATYA BHUJANGA RAO ADIBHATLA, DURGA MAHESWARI PARVATANENI, SIDDHARTHA YEDLURI
Format Patent
LanguageEnglish
Spanish
Published 06.12.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like. Una formulación farmacéutica oral que contiene una cantidad efectiva de NRCAN-019 incluyendo sus sales farmacéuticamente aceptables y polimorfos tales como Forma I, Forma II y Forma III del mismo para mejorar la biodisponibilidad destinada para auto-emulsificación al hacer contacto con el fluido gastrointestinal. La invención también se refiere a un procedimiento para la preparación de solución oral que contiene NRC-AN-019 en una concentración efectiva para la mejor terapia contra leucemia mieloide crónica como inhibidor de •tirosina quinasa de BCR-ABL y contra otros tumores tales como cáncer de cabeza y cuello, cáncer de próstata y similares.
Bibliography:Application Number: MX20130010160